Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

S. Cora Verduyn, Bonne Biesma, Franz M. N. H. Schramel, Feike W. van der Scheer, Merel K. Langenfeld*, Maria A. de Peuter, Anne-Marie C. Dingemans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)
Original languageEnglish
Pages (from-to)108
JournalHealth and Quality of Life Outcomes
Publication statusPublished - 10 Sep 2012


  • Advanced non-small cell lung cancer
  • Tyrosine kinase inhibitors
  • EGFR mutation
  • Gefitinib
  • Quality of life
  • Progression free survival

Cite this